PP2 protects from keratin mutation–associated liver injury and filament disruption via SRC kinase inhibition in male but not female mice
P Li, D Maitra, N Kuo, R Kwan, Y Song, W Tang… - Hepatology, 2023 - journals.lww.com
P Li, D Maitra, N Kuo, R Kwan, Y Song, W Tang, L Chen, Q Xie, L Liu, MB Omary
Hepatology, 2023•journals.lww.comConclusions: PP2 protects, in a male‐selective manner, keratin mutation‐induced mouse
liver injury by inhibiting SRC‐triggered downstream Ser/Thr phosphorylation of K8/K18,
which is phenocopied by RAF kinase inhibitor vemurafenib. The PP2/vemurafenib‐
associated findings, and their unique mechanisms of action, further support the potential role
of select kinase inhibition as therapeutic opportunities for keratin and other IF‐associated
human diseases.
liver injury by inhibiting SRC‐triggered downstream Ser/Thr phosphorylation of K8/K18,
which is phenocopied by RAF kinase inhibitor vemurafenib. The PP2/vemurafenib‐
associated findings, and their unique mechanisms of action, further support the potential role
of select kinase inhibition as therapeutic opportunities for keratin and other IF‐associated
human diseases.
Conclusions:
PP2 protects, in a male‐selective manner, keratin mutation‐induced mouse liver injury by inhibiting SRC‐triggered downstream Ser/Thr phosphorylation of K8/K18, which is phenocopied by RAF kinase inhibitor vemurafenib. The PP2/vemurafenib‐associated findings, and their unique mechanisms of action, further support the potential role of select kinase inhibition as therapeutic opportunities for keratin and other IF‐associated human diseases.
Lippincott Williams & Wilkins